number
smallmolecul
drug
inhibit
viral
replic
bind
directli
virion
structur
protein
activ
site
viral
enzym
chemic
modifi
viral
enzym
inhibit
downstream
process
similarli
antibodi
use
prevent
treat
viral
infect
attach
epitop
virion
viral
protein
express
surfac
infect
cell
drug
antibodi
therefor
thought
probe
detect
viral
infect
suggest
might
use
radiolabel
tracer
visual
site
viral
replic
singlephoton
emiss
comput
tomographi
spect
positron
emiss
tomographi
pet
imag
current
exampl
approach
pet
imag
herp
simplex
viru
infect
viral
thymidin
kinas
phosphoryl
radiolabel
thymidin
analogu
trap
within
infect
cell
one
mani
possibl
futur
applic
might
use
radiolabel
hepat
c
proteas
inhibitor
imag
infect
anim
human
provid
quantit
measur
viral
burden
articl
review
basic
featur
radionuclid
imag
characterist
ideal
tracer
molecul
discuss
antivir
drug
antibodi
could
evalu
suitabl
virusspecif
imag
probe
use
label
drug
lowdos
tracer
would
provid
altern
applic
compound
fail
advanc
clinic
use
insuffici
vivo
potenc
unsuit
pharmacokinet
profil
hepatoor
nephrotox
publish
elsevi
bv
radionuclid
imag
techniqu
singlephoton
emiss
comput
tomographi
spect
positron
emiss
tomographi
pet
employ
shortliv
radiolabel
tracer
visual
biochem
process
anim
human
select
retent
imag
probe
site
interest
base
either
highaffin
bind
specif
target
hormon
receptor
occurr
specif
chemic
modif
phosphoryl
trap
within
cell
fig
mani
differ
tracer
molecul
employ
studi
varieti
pathophysiolog
process
appli
virolog
research
spect
pet
use
almost
exclus
imag
host
respons
infect
rather
visual
viral
replic
instanc
pathogenspecif
tracer
employ
detect
track
viru
use
radiolabel
thymidin
analogu
imag
herp
simplex
viru
hsv
infect
base
phosphoryl
probe
viral
thymidin
kinas
tk
trap
within
infect
cell
fig
brader
et
al
kuruppu
et
al
articl
examin
question
whether
virus
hsv
could
imag
spect
pet
use
radiolabel
antivir
drug
antibodi
probe
case
hepat
c
exampl
tracer
might
includ
molecul
block
viral
replic
bind
specif
virusencod
molecul
proteas
fig
contrast
antivir
compound
ribavirin
phosphoryl
retain
within
infect
uninfect
cell
would
suitabl
probe
virusspecif
imag
begin
provid
overview
principl
radionuclid
imag
note
similar
differ
mechan
action
antivir
drug
imag
probe
describ
spect
pet
use
detect
host
respons
viral
infect
examin
pet
employ
track
distribut
radiolabel
antivir
drug
uninfect
subject
next
show
recent
develop
recombin
oncolyt
virus
encod
host
report
molecul
provid
proof
concept
virusspecif
imag
examin
research
taken
advantag
select
phosphoryl
thymidin
analogu
hsv
tk
imag
hsv
infect
tk
also
use
recombin
marker
imag
tumor
gene
therapi
condit
next
identifi
number
process
uniqu
viral
replic
might
serv
target
radiolabel
pathogenspecif
tracer
review
nine
differ
dna
rna
viru
famili
identifi
approv
experiment
antivir
drug
target
virusencod
molecul
might
potenti
radiolabel
probe
conclud
explain
research
determin
potenti
antivir
drug
antibodi
radiolabel
imag
probe
use
hor
clabel
compound
simpl
vitro
ex
vivo
experi
antivir
therapi
nuclear
medicin
share
common
origin
effort
paul
ehrlich
develop
antimicrobi
medic
earli
concept
magic
bullet
base
observ
certain
dye
stain
microb
surround
cell
tissu
section
suggest
select
bind
small
molecul
pathogen
could
exploit
therapeut
purpos
find
substanc
specif
inhibit
treponema
pallidum
ehrlich
test
compound
vari
side
chain
found
one
toxic
spirochet
host
two
decad
later
georg
de
hevesi
follow
line
reason
use
radioact
compound
tracer
explor
mechan
drug
action
time
bismuth
compon
number
compound
employ
treatment
syphili
determin
distribut
within
bodi
de
hevesi
introduc
radioact
bismuth
medic
inocul
bloodstream
rabbit
follow
distribut
clearanc
blood
tissu
hevesi
paneth
lomholt
concept
use
lowdos
radioact
tracer
studi
biochem
process
directli
particip
still
follow
today
develop
probe
target
cell
surfac
intracellular
receptor
enzym
molecul
eckelman
et
al
phelp
rudin
et
al
respect
basic
mechan
underli
radionuclid
imag
similar
antivir
therapi
drug
produc
benefici
effect
within
region
interest
locu
viral
infect
minim
impact
tissu
optim
pharmacokinet
properti
antivir
agent
differ
howev
ideal
imag
probe
continu
high
drug
level
blood
tissu
benefici
therapi
spect
pet
imag
persist
tracer
would
result
high
background
signal
poor
imag
contrast
discuss
ideal
imag
probe
differ
drug
retain
site
interest
clear
rapidli
nontarget
tissu
spect
pet
imag
base
use
radiolabel
probe
select
retain
site
specif
physiolog
process
photon
emit
probe
regist
detector
signal
translat
comput
antibodi
peptid
larg
highli
charg
diffus
cell
membran
use
target
antigen
receptor
cell
surfac
small
molecul
transport
diffus
across
cell
membran
may
retain
cytoplasm
nucleu
bind
receptor
target
altern
probe
may
undergo
phosphoryl
cellular
eg
hexokinas
viral
hsvtk
enzym
diffus
cell
figur
fabian
de
kokmercado
visibl
imag
spect
imag
photon
energi
rang
kev
impact
sodium
iodid
crystal
detector
within
camera
head
revolv
around
subject
enabl
assembl
threedimension
imag
fig
photon
outsid
region
interest
nonspecif
scatter
aris
within
subject
block
collim
perfor
metal
block
place
front
detector
increas
signaltonois
ratio
snr
spect
camera
determin
direct
gamma
ray
sourc
accur
depth
within
bodi
method
spatial
resolut
order
mm
contrast
registr
singl
photon
rang
energi
spect
pet
detect
pair
kev
photon
releas
opposit
direct
positron
emit
probe
within
bodi
tissu
collid
electron
fig
pet
instrument
therefor
configur
ring
detector
surround
subject
regist
signal
two
photon
correct
energi
strike
opposit
side
ring
simultan
snr
markedli
increas
intrins
mechan
allow
pet
provid
better
spatial
resolut
spect
approxim
mm
clinic
imag
mm
anim
micropet
system
facilit
accur
quantit
radioact
decay
within
region
interest
quantit
data
lend
statist
analysi
patholog
abnorm
assess
respons
treatment
especi
use
monitor
cancer
therapi
consider
design
spect
pet
probe
locat
imag
target
cell
surfac
within
cell
first
question
consid
design
imag
probe
locat
intend
target
cell
surfac
access
directli
bloodstream
within
cell
reach
tracer
capabl
travers
lipid
bilay
cellsurfac
target
imag
use
antibodi
antibodi
fragment
peptid
larg
charg
molecul
reach
target
plasma
exampl
radiolabel
antibodi
use
detect
quantit
cell
lymphoid
tissu
retrovirusinfect
macaqu
fig
di
mascio
et
al
contrast
target
cytoplasm
nucleu
size
charg
becom
critic
consider
effect
tracer
gener
small
nonpolar
molecul
target
locat
chemic
properti
tracer
also
affect
time
requir
obtain
suitabl
highcontrast
imag
high
molecular
weight
probe
clear
slowli
nontarget
tissu
smaller
molecul
may
necessari
label
radionuclid
longer
halflif
discuss
greater
detail
pharmacokinet
consider
affect
imag
contrast
snr
determin
long
take
tracer
clear
area
site
interest
case
licens
medic
consid
use
radiolabel
probe
clearanc
data
may
alreadi
obtain
pharmacokinet
studi
natur
target
satur
nonsatur
interact
drug
probe
target
divid
two
differ
type
reach
maximum
level
activ
becom
satur
concentr
drug
probe
increas
continu
display
greater
activ
concentr
increas
nonsatur
target
satur
target
antivir
therapi
gener
therapeut
molecul
occupi
target
site
limit
number
site
avail
bind
exampl
includ
bind
pleconaril
within
cleft
capsid
picornavirus
block
influenza
ion
channel
amantadin
bind
nonnucleosid
revers
transcriptas
rt
inhibitor
locu
hiv
rt
distinct
activ
site
radionuclid
imag
exampl
satur
target
includ
betaadrenerg
muscarin
estrogen
receptor
bind
label
analogu
eckelman
et
al
katzenellenbogen
et
al
sever
factor
determin
whether
radiolabel
probe
bind
satur
target
gener
use
imag
first
probe
must
need
pharmacokinet
properti
reach
target
see
second
high
affin
bind
site
measur
k
concentr
bind
site
occupi
equilibrium
third
must
suffici
number
target
within
region
interest
accumul
bound
tracer
result
detect
signal
practic
mean
possibl
imag
lowdens
target
long
k
tracertarget
interact
nanomolar
rang
less
fraction
label
probe
molecul
specif
activ
high
condit
met
minut
quantiti
tracer
much
small
caus
pharmacolog
effect
produc
imag
jagoda
et
al
eckelman
eckelman
et
al
eckelman
et
al
compound
toxic
therapeut
use
might
therefor
still
find
applic
imag
probe
contrast
target
nonsatur
probe
gener
enzym
alter
chemic
structur
probe
manner
favor
retent
target
site
antivir
therapi
classic
nonsatur
target
hsv
tk
phosphoryl
acyclovir
caus
accumul
within
hsvinfect
cell
describ
properti
hsv
tk
also
permit
extens
use
recombin
enzym
imag
report
spect
pet
princip
applic
nonsatur
target
radionuclid
imag
make
use
dg
glucos
molecul
lack
group
readili
phosphoryl
host
cell
hexokinas
metabol
remain
trap
within
cell
fig
dg
label
posit
form
fdg
fdg
without
chang
metabol
activ
malign
cell
tend
high
rate
glucos
metabol
dg
origin
test
anticanc
drug
prove
toxic
clinic
use
woodward
hudson
pauwel
et
al
low
dose
howev
fdg
toxic
use
probe
label
cell
high
glycolyt
activ
fdg
wide
use
identifi
foci
increas
glucos
metabol
tumor
site
inflamm
pet
imag
fig
de
winter
et
al
kumar
et
al
contrast
imag
satur
target
signal
strength
determin
number
radiolabel
probe
molecul
bind
desir
site
success
imag
nonsatur
target
limit
number
target
within
region
interest
exampl
ffdg
use
visual
site
high
glucos
metabol
influx
neutrophil
occur
respons
endotoxin
affect
cell
accumul
larg
amount
phosphoryl
label
amplifi
signal
chen
et
al
chen
schuster
bring
select
retent
phosphoryl
acyclovir
thymidin
analogu
within
infect
cell
hsv
tk
provid
similar
advantag
antivir
therapi
imag
signal
amplif
inher
use
nonsatur
target
specif
activ
probe
number
target
site
less
critic
consider
acquisit
use
imag
practic
term
make
possibl
tracer
ffdg
store
longer
synthesi
administr
subject
one
compens
diminish
radioact
probe
give
larger
dose
satur
target
contrast
delay
could
impair
imag
acquisit
tracer
molecul
undergon
radioact
decay
compet
label
probe
avail
bind
site
radioisotop
virologist
medicin
chemist
familiar
h
c
weak
betaemitt
halfliv
measur
year
hydrogen
carbon
constitu
element
allantivir
medic
isotop
introduc
drug
synthesi
product
differ
structur
biolog
properti
unlabel
compound
long
halfliv
also
mean
hand
clabel
drug
store
use
year
without
loss
activ
employ
vivo
pharmacokinet
studi
compound
detect
blood
urin
tissu
sampl
scintil
count
beta
decay
trigger
emiss
photon
light
key
differ
isotop
shortliv
radionuclid
use
pet
spect
imag
pet
base
positronelectron
annihal
yield
pair
kev
photon
high
energi
minim
attenu
scatter
passag
soft
tissu
spect
isotop
hand
emit
photon
lower
energi
rang
kev
like
scatter
absorb
addit
degrad
imag
qualiti
worsen
target
detector
advantag
spect
howev
variou
tracer
emit
photon
rang
energi
peak
possibl
imag
one
target
session
set
instrument
comput
algorithm
separ
signal
differ
energi
pet
isotop
contrast
produc
photon
energi
make
necessari
perform
separ
imag
session
two
differ
probe
use
studi
subject
shown
tabl
mani
differ
radioisotop
use
label
spect
pet
probe
choic
one
use
particular
studi
base
number
consider
avail
imag
instrument
access
cyclotron
expertis
radiochemistri
laboratori
technic
challeng
incorpor
given
isotop
probe
latter
point
includ
question
chemic
stabil
result
molecul
retent
biolog
activ
halflif
select
radionuclid
also
consist
expect
clearanc
time
tracer
ensur
suffici
radioact
detect
region
interest
provid
use
imag
need
chemic
stabil
short
halflif
potenti
met
perform
pet
imag
clabel
probe
replac
one
carbon
atom
anoth
synthesi
leav
molecul
physiolog
activ
unchang
halflif
make
possibl
imag
subject
repeatedli
interv
hour
howev
isotop
short
halflif
mean
use
practic
one
possess
onsit
cyclotron
adequ
radiochemistri
support
lack
resourc
would
better
use
flabel
probe
halflif
make
possibl
synthesi
take
place
offsit
still
allow
subject
imag
twice
daili
limit
approach
introduct
fluorin
atom
probe
may
requir
difficult
chemic
synthesi
may
also
alter
molecul
biochem
characterist
case
antivir
efficaci
therefor
essenti
test
activ
probe
vitro
ensur
biolog
activ
retain
tabl
radionuclid
commonli
employ
pet
imag
advantag
disadvantag
method
radionuclid
incorpor
imag
probe
fall
two
broad
categori
tracer
molecul
origin
chemic
structur
remain
unchang
structur
modifi
permit
addit
radioact
moieti
first
approach
includ
introduct
radionuclid
primari
synthet
reaction
direct
exchang
stabl
counterpart
second
includ
three
differ
techniqu
chemic
modif
origin
molecul
permit
addit
radiolabel
addit
origin
molecul
structur
alreadi
contain
radiolabel
addit
origin
molecul
chemic
structur
noncoval
bind
chelat
isotop
matter
label
perform
criteria
success
importantli
addit
radionuclid
interfer
highaffin
bind
tracer
target
label
also
reduc
lipophil
probe
must
pass
cell
membran
cross
bloodbrain
barrier
reach
target
prevent
interact
specif
transport
system
final
attach
radionuclid
probe
suffici
stabl
ensur
remain
place
carri
bloodstream
target
success
vivo
imag
depend
upon
proper
system
distribut
cellular
uptak
elimin
tracer
follow
administr
ensur
rapid
uniform
deliveri
throughout
bodi
imag
probe
administ
intraven
inject
note
pharmacokinet
virusspecif
imag
probe
resembl
ideal
antivir
drug
term
uptak
infect
cell
differ
therapeut
agent
clear
quickli
uninfect
tissu
pharmacokinet
pattern
would
provid
optim
contrast
site
viral
replic
normal
tissu
clearanc
take
time
radioisotop
must
long
enough
halflif
ensur
adequ
activ
remain
region
interest
background
signal
reach
low
level
maxim
targettobackground
ratio
contrast
antivir
therapi
desir
drug
concentr
tissu
tend
micromolar
rang
radiotrac
concentr
typic
picoto
nanomolar
rang
radionuclid
imag
use
studi
viral
diseas
three
decad
employ
indirect
method
identifi
site
infect
begin
found
cytomegaloviru
pneumon
infect
immunodefici
patient
could
detect
administ
small
intraven
dose
ga
citrat
imag
gamma
camera
hame
et
al
reinder
folmer
et
al
result
increas
perfus
enhanc
vascular
permeabl
radionuclid
accumul
site
infect
approach
includ
intraven
infus
inlabel
polyclon
human
immunoglobulin
patient
intag
leukocyt
buscomb
et
al
kumar
although
techniqu
detect
presenc
infect
identifi
caus
agent
microbiolog
diagnosi
must
obtain
collect
appropri
sampl
perform
laboratori
test
fdgpet
imag
increasingli
use
studi
host
respons
infect
especi
research
set
describ
techniqu
reli
preferenti
retent
phosphoryl
ffdg
cell
high
level
glucos
metabol
occur
infecti
inflammatori
process
love
et
al
tabl
radionuclid
commonli
employ
spect
imag
advantag
disadvantag
macki
earli
hiv
pandem
exampl
fdgpet
use
demonstr
zidovudin
therapi
benefici
effect
patient
hivrel
dementia
shown
measur
reduct
cerebr
ffdg
retent
brunetti
et
al
yarchoan
et
al
techniqu
shown
peripher
lymph
node
greater
glucos
uptak
untreat
hivinfect
individu
patient
antiretrovir
therapi
indic
lymph
node
site
viral
replic
brust
et
al
fdgpet
use
recent
character
patient
sever
swineorigin
influenza
show
intens
inflammatori
respons
present
area
dens
pulmonari
consolid
seen
ct
scan
region
aerat
lung
fig
bellani
et
al
bellani
et
al
valu
studi
would
obvious
enhanc
patient
could
also
imag
influenzavirusspecif
probe
determin
rel
chronolog
physic
distribut
viral
replic
host
inflammatori
respons
wholebodi
pet
imag
use
supplement
tradit
method
measur
uptak
distribut
excret
antivir
drug
laboratori
anim
exampl
pet
use
studi
pharmacokinet
tenofovir
analogu
fpmpa
rat
reveal
increas
concentr
renal
cortex
appear
correspond
drug
occasion
nephrotox
human
fig
di
mascio
et
al
similarli
effort
understand
caus
neurolog
side
effect
antiinfluenza
drug
oseltamivir
investig
employ
pet
examin
uptak
retent
clabel
drug
brain
mice
hatori
et
al
konno
et
al
although
studi
pharmacokinet
clabel
stavudin
rat
base
measur
radioact
excis
tissu
author
note
question
could
answer
vivo
imag
livni
et
al
pet
also
use
follow
deposit
retent
inhal
dose
radiolabel
zanamivir
anoth
inhibitor
influenza
viral
neuraminidas
human
subject
bergstrom
et
al
cass
et
al
studi
involv
uninfect
individu
evid
procedur
could
use
track
distribut
zanamavir
person
infect
season
influenza
virus
either
treatment
experi
would
help
determin
effect
therapi
cours
ill
would
reveal
whether
radiolabel
drug
could
use
detect
track
spread
viru
respiratori
tract
nascent
field
cancer
virotherapi
exploit
abil
virus
replic
select
malign
cell
novel
approach
kill
tumor
monitor
replic
oncolyt
viru
recombin
agent
construct
encod
report
radionuclid
imag
exampl
includ
recombin
vaccinia
viru
encod
human
norepinephrin
transport
enabl
pet
imag
caus
imetaiodobenzylguanidin
mibg
accumul
within
infect
cell
fig
goel
et
al
herpesvirus
also
use
experiment
oncolyt
agent
case
viru
tk
provid
report
pet
spect
imag
see
strategi
introduc
gene
encod
imag
report
viral
genom
provid
proof
concept
notion
employ
natur
occur
virusencod
molecul
target
radiolabel
imag
probe
approach
describ
howev
signific
limit
would
seen
use
unmodifi
viru
introduct
addit
gene
may
interfer
significantli
viral
replic
problem
observ
exampl
gene
encod
green
fluoresc
protein
introduc
ebola
zair
viru
although
modifi
agent
replic
normal
cell
cultur
attenu
mice
ebihara
et
al
ideal
imag
approach
studi
viral
infect
laboratori
anim
therefor
make
use
unmodifi
pathogen
possibl
use
natur
occur
virusencod
molecul
imag
report
first
explor
earli
acyclovir
approv
antivir
drug
treatment
hsv
infect
abil
nucleosid
analogu
select
inhibit
hsv
replic
base
abil
undergo
phosphoryl
viral
thymidin
kinas
tk
correspond
host
enzym
tk
support
dna
synthesi
divid
cell
pathogen
replic
phosphoryl
hydroxyl
group
deoxythymidin
dt
produc
dtmp
convert
triphosph
form
cellular
kinas
eriksson
et
al
multicellular
organ
bacteria
possess
tk
enzym
also
encod
larg
dna
virus
gentri
two
famili
tk
enzym
recogn
base
chemic
structur
substrat
specif
devillebonn
et
al
first
group
includ
enzym
found
cytoplasm
human
cell
tetramer
molecul
phosphoryl
dt
deoxyuridin
use
atp
phosphat
donor
welin
et
al
express
sphase
cell
cycl
therefor
present
signific
quantiti
divid
cell
label
deoxythymidin
analogu
flt
therefor
use
probe
select
imag
tumor
pet
langen
et
al
shield
member
enzym
famili
includ
poxvir
tk
similarli
narrow
rang
substrat
specif
gentri
second
class
tk
consist
homodimer
enzym
abl
phosphoryl
rang
substrat
includ
varieti
nucleosid
analogu
eriksson
et
al
group
includ
second
human
enzym
found
low
concentr
mitochondria
also
includ
tk
encod
alphaherpesvirus
hsv
bestknown
member
broad
substrat
specif
hsv
tk
basi
antivir
therapi
acyclovir
nucleosid
analogu
acyclovir
enter
cell
bloodstream
diffus
activ
transport
across
cell
membran
uninfect
cell
drug
modifi
minim
amount
phosphoryl
mitochondri
almost
diffus
back
bloodstream
elimin
kidney
hsvinfect
cell
howev
viral
tk
convert
acyclovir
monophosph
convert
cellular
kinas
triphosph
acycylovir
triphosph
greater
affin
hsv
dna
polymeras
host
enzym
preferenti
incorpor
replic
viral
genom
caus
chain
termin
elion
select
retent
acyclovir
relat
antivir
hsvinfect
cell
rapid
clearanc
uninfect
tissu
enhanc
potenti
util
imag
probe
increas
targettobackground
ratio
recent
effort
imag
hsv
infect
focus
detect
monitor
viral
enceph
laboratori
anim
begin
earli
investig
succeed
show
even
though
bloodbrain
barrier
normal
restrict
entri
deoxythymidin
analogu
central
nervou
system
increas
permeabl
associ
viral
infect
permit
entri
suffici
amount
probe
label
infect
cell
seri
studi
rat
infect
intraocularli
appropri
interv
inject
intraven
small
dose
clabel
fmau
ior
ilabel
deoxyuridin
ivdu
gill
et
al
klapper
et
al
price
et
al
saito
et
al
cleator
et
al
foci
enceph
identifi
either
kill
anim
perform
autoradiographi
brain
slice
imag
live
anim
use
gamma
camera
howev
weak
signal
obtain
similar
studi
perform
recent
use
clabel
fmau
result
vivo
imag
shown
de
vri
et
al
gener
experi
shown
limit
transport
probe
across
bloodbrain
barrier
significantli
restrict
util
radionuclid
imag
hsv
enceph
contrast
discourag
result
success
pet
imag
hsv
infect
recent
report
differ
area
research
use
virus
experiment
cancer
therapi
herpesvirus
one
number
agent
explor
capac
infect
kill
tumor
cell
fact
natur
encod
tk
mean
replic
laboratori
anim
readili
monitor
radionuclid
imag
viral
replic
tumor
virual
use
sever
differ
radiolabel
deoxythymidin
analogu
f
feau
fig
brader
et
al
fiau
jacob
et
al
f
hydroxymethyl
butyl
guanin
fhbg
kuruppu
et
al
work
thu
repres
first
success
imag
viral
replic
live
anim
target
natur
occur
virusencod
report
radiolabel
probe
beta
herpesviru
cytomegaloviru
cmv
encod
tk
employ
protein
kinas
phosphoryl
nucleosid
recogn
acyclovir
limit
extent
drug
use
treat
cmv
infect
howev
new
compound
greater
anticmv
activ
ganciclovir
introduc
medic
practic
flabel
analogu
ganciclovir
methyl
guanin
fhpg
evalu
probe
imag
cmv
infect
alauddin
et
al
de
vri
et
al
pet
scan
use
ffhpg
shown
correctli
identifi
cmv
enceph
rat
confirm
autoradiographi
util
approach
limit
restrict
entri
probe
across
bloodbrain
barrier
buursma
et
al
tk
gene
compar
small
possibl
insert
genom
virus
provid
report
radionuclid
imag
exampl
recombin
hiv
simian
immunodefici
siv
virus
encod
tk
construct
use
parent
virus
lack
nef
gene
attenu
creat
space
addit
genom
materi
chakrabarti
et
al
although
origin
envis
live
vaccin
would
safe
use
sensit
ganciclovir
recombin
agent
could
also
employ
studi
retrovir
infect
anim
spect
pet
addit
use
tk
molecul
extens
exploit
report
spect
pet
imag
malign
assess
gene
therapi
miyagawa
et
al
serganova
et
al
novel
therapeut
approach
hsv
har
kill
malign
cell
distribut
replic
monitor
pet
imag
use
ifiau
tracer
bennett
et
al
kuruppu
et
al
recent
shown
treatment
herpesvirusinduc
cancer
burkitt
lymphoma
anticanc
drug
bortezomib
trigger
express
viral
tk
make
possibl
tumor
visual
pet
potenti
treat
ganciclovir
fu
et
al
note
poxvirus
also
encod
tk
type
ii
enzym
howev
substrat
specif
similar
human
cell
poxvirus
suscept
acyclovir
treatment
instead
reli
nucleotid
analogu
cidofovir
enter
cell
macropinocytosi
convert
biand
triphosph
cellular
kinas
drug
therefor
inhibit
herpesvirus
poxvirus
initi
phosphoryl
perform
host
enzym
accumul
normal
cell
make
unsuit
use
virusspecif
imag
agent
interestingli
recent
research
identifi
thymidin
analogu
inhibit
replic
wildtyp
vaccinia
viru
significantli
better
viru
lack
tk
gene
suggest
mechan
action
resembl
acyclovir
prichard
et
al
prichard
et
al
howev
compound
also
process
extent
host
tk
probabl
littl
valu
imag
interest
parallel
viral
infect
mani
genera
bacteria
encod
type
tk
make
suscept
antih
fig
petct
imag
septic
arthriti
right
knee
patient
use
bacteri
tk
report
ifiau
probe
diaz
et
al
permiss
pesvir
drug
imag
research
taken
advantag
properti
visual
musculoskelet
infect
mice
human
patient
exampl
recent
studi
employ
ifiau
pet
probe
detect
staphylococc
infect
follow
joint
surgeri
fig
bettegowda
et
al
diaz
et
al
approach
use
imag
mycobacterium
tuberculosi
anim
even
though
organ
lack
tk
introduc
gene
escherichia
coli
tk
mycobacteri
strain
research
abl
use
ifiau
visual
site
infect
spect
davi
et
al
natur
occur
virusencod
molecul
employ
radionuclid
imag
hsv
tk
seem
unlik
enzym
possibl
target
virusspecif
imag
follow
section
review
basic
step
viral
replic
could
exploit
pet
spect
number
step
identifi
hepat
c
viru
replic
cycl
fig
infect
cell
viru
must
first
bind
surfac
usual
specif
receptor
undergo
process
fusion
cell
membran
lead
disassembl
capsid
releas
content
cytoplasm
fusion
process
virion
surfac
protein
undergo
specif
conform
chang
expos
hydrophob
peptid
sequenc
interact
lipid
bilay
fig
agent
retrovirus
enter
directli
cell
surfac
other
membran
fusion
take
place
within
endosom
trigger
acidif
case
peptid
inhibitor
identifi
wide
rang
virus
specif
block
entri
process
viral
genom
deliv
cytoplasm
gene
transcript
genom
product
depend
upon
readi
suppli
nucleotid
deoxynucleotid
synthesi
new
rna
type
virus
dna
dna
virus
major
antivir
strategi
therefor
design
analogu
accept
substrat
viral
rna
dna
polymeras
result
either
chain
termin
incorpor
polynucleotid
impair
subsequ
function
drug
inhibit
viral
polymeras
convert
monophosph
cellular
kinas
therefor
trap
within
infect
uninfect
cell
would
suitabl
virusspecif
imag
probe
altern
approach
success
hiv
therapi
use
target
hepat
c
virus
identifi
nonnucleosid
molecul
bind
locu
surfac
viral
polymeras
rather
activ
site
induc
conform
chang
block
enzymat
activ
fig
molecul
undergo
initi
process
host
enzym
potenti
serv
virusspecif
probe
anoth
potenti
target
pathogenspecif
tracer
virusencod
helicas
separ
strand
doublestrand
dna
rna
molecul
case
retrovirus
dnarna
molecul
cours
transcript
genom
replic
specif
inhibitor
helicas
number
virus
develop
candid
drug
may
also
potenti
imag
probe
transcript
take
place
viral
mrna
must
modifi
ensur
effici
translat
format
methyl
cap
methyl
process
prove
fruit
target
antivir
therapi
howev
although
compound
inhibit
methyl
block
host
cell
enzym
sadenosylhomocytein
hydrolas
potent
broadspectrum
antivir
activ
would
suitabl
virusspecif
probe
bind
viral
target
contrast
compound
specif
block
virusencod
methyltransferas
flaviviru
protein
might
make
good
tracer
radionuclid
imag
dong
et
al
translat
viral
mrna
host
cell
proteinsynthet
machineri
often
follow
cleavag
protein
product
matur
form
case
positivesens
singlestrand
rna
virus
exampl
entir
genom
first
translat
one
larg
polyprotein
cleav
individu
compon
cellular
enzym
endogen
proteas
fig
differ
host
cell
activ
site
number
viral
proteas
proven
reward
target
antivir
drug
number
compound
identifi
bind
irrevers
high
specif
activ
site
proteas
could
potenti
use
radiolabel
probe
nucleocapsid
virion
structur
compon
gener
carri
endogen
transport
pathway
inner
surfac
cell
membran
assembl
releas
viral
particl
take
place
effort
develop
specif
inhibitor
process
way
drug
yet
shown
protect
activ
vivo
harti
transport
pathway
share
uninfect
cell
unlik
drug
block
mechan
could
use
pathogenspecif
tracer
molecul
viral
envelop
protein
accumul
cell
surfac
cours
replic
anchor
lipophil
peptid
sequenc
fig
surfac
marker
make
infect
cell
vulner
immun
system
bind
specif
antibodi
subsequ
cellmedi
destruct
could
also
target
probe
radiolabel
antibodi
interestingli
certain
tumor
induc
viral
infect
ebvassoci
lymphoma
hepatocellular
carcinoma
patient
hepat
b
c
cervic
carcinoma
induc
papillomavirus
express
viral
antigen
make
vulner
destruct
antibodi
tag
highenergi
alpha
emitt
dadachova
et
al
suggest
strategi
could
use
erad
hiv
individu
low
level
residu
infect
casadeval
et
al
similar
strategi
use
antibodi
label
gammaray
positronemit
isotop
might
use
spect
pet
imag
could
drug
antihsv
medic
use
visual
viral
infect
spect
pet
licens
antivir
nucleosid
nucleotid
analogu
undergo
initi
phosphoryl
cellular
kinas
therefor
could
serv
pathogenspecif
probe
howev
note
replic
cycl
variou
dna
rna
virus
offer
varieti
target
drug
probe
interact
specif
virusencod
molecul
follow
section
identifi
exampl
candid
tracer
nine
differ
viru
famili
smallmolecul
drug
inhibit
replic
junin
new
world
arenavirus
benzimidazol
deriv
target
old
world
agent
lassa
viru
bolken
et
al
larson
et
al
base
mutagenesi
studi
virion
surfac
molecul
compound
interfer
viral
entri
specif
mechan
known
extens
requir
protein
cleavag
coronaviru
replic
cycl
made
viral
papainlik
plpro
chymotrypsinlik
proteas
major
target
drug
develop
highli
specif
smallmolecul
inhibitor
enzym
identifi
inhibit
sar
coronaviru
might
also
use
imag
infect
ratia
et
al
fig
identif
potenti
target
inhibitor
flavivir
proteas
dengu
viru
block
replic
without
caus
cellular
toxic
suggest
specif
viral
target
lescar
et
al
smallmolecul
biln
bind
activ
site
hepat
c
viru
effect
reduc
viral
load
patient
lamarr
et
al
although
develop
halt
evid
cardiotox
would
necessarili
prevent
compound
use
low
dosag
imag
probe
drug
directli
inhibit
virusencod
methyltransferas
current
develop
dengu
west
nile
flavivirus
dong
et
al
nonnucleosid
molecul
identifi
inhibit
rnadepend
rna
polymeras
bovin
pestiviru
paeshuys
et
al
other
evalu
treatment
hepat
c
ctermin
portion
flaviviru
molecul
helicas
essenti
replic
inhibitor
identifi
hepat
c
flavivirus
leyssen
et
al
lescar
et
al
hepat
c
virion
surfac
glycoprotein
express
surfac
infect
cell
make
potenti
target
antibodydepend
cellular
cytotox
imag
radiolabel
antibodi
fragment
label
dna
aptam
drummer
et
al
nattermann
et
al
chen
et
al
protein
kinas
cmv
carri
multipl
function
includ
nucleosid
phosphoryl
prichard
recent
discov
antivir
mirabavir
inhibit
enzym
suggest
could
use
radiolabel
tracer
imag
cmv
infect
prototyp
drug
bind
directli
virion
inhibit
replic
adamantan
amantadin
rimantidin
block
ion
channel
prevent
core
acidif
requir
virion
disassembl
endosom
beigel
bray
specif
natur
interact
suggest
small
dose
radiolabel
amantadin
rimantadin
could
use
local
influenza
viru
infect
track
spread
laboratori
anim
human
two
licens
drug
oseltamivir
zanamivir
inhibit
celltocel
spread
influenza
b
virus
bind
neuraminidas
activ
site
beigel
bray
specif
interact
might
make
effect
imag
probe
note
distribut
inhal
czanamavir
visual
pet
healthi
human
volunt
bergstrom
et
al
studi
perform
influenzainfect
patient
could
provid
use
inform
drug
distribut
extent
viral
infect
two
smallmolecul
compound
block
entri
respiratori
syncyti
viru
rsv
cell
low
nanomolar
concentr
bind
small
hydrophob
pocket
center
f
protein
dougla
et
al
rsv
f
protein
also
target
human
mab
palivizumab
use
prevent
infect
highrisk
infant
georgescu
chemali
new
antibodi
motavizumab
greater
virusspecif
bind
affin
lower
degre
nonspecif
bind
host
tissu
recent
develop
wu
et
al
conserv
heptad
repeat
region
fusion
protein
highli
virul
paramyxovirus
hendra
nipah
target
peptid
mimic
block
infect
vitro
low
nanomolar
concentr
porotto
et
al
recent
discov
compound
block
format
rsv
nucleocapsid
bind
specif
site
n
protein
submicromolar
concentr
chapman
et
al
phase
ii
clinic
trial
entri
picornavirus
cell
requir
disrupt
interact
among
four
capsid
protein
releas
viral
genom
cytoplasm
number
compound
identifi
insert
pocket
virion
surfac
stabil
capsid
prevent
disassembl
de
palma
et
al
compound
protect
mice
lethal
polioviru
infect
pleconaril
act
mechan
extens
test
antirhinoviru
activ
human
de
palma
et
al
mckinlay
steinberg
highli
specif
interact
compound
viral
capsid
suggest
could
use
imag
site
picornavir
infect
proteas
human
rhinoviru
inhibit
number
compound
includ
smallmolecul
rupintrivir
bind
irrevers
enzym
activ
site
de
palma
et
al
viral
enzym
known
human
homologu
good
target
virusspecif
imag
benzimidazol
analogu
enviroxim
inhibit
replic
rhinovirus
enterovirus
block
viral
rna
replic
appar
directli
inhibit
action
protein
compound
protect
mice
lethal
coxsacki
myocard
shown
activ
protect
human
rhinovirus
victor
et
al
de
palma
et
al
complex
process
poxvirus
exit
cell
provid
target
antivir
therapi
smallmolecul
interact
specif
vaccinia
viru
protein
involv
addit
membran
layer
need
form
extracellular
envelop
virion
yang
et
al
duraffour
et
al
nontox
mammalian
cell
anim
human
suggest
uniqu
target
viral
enzym
could
therefor
use
radiolabel
probe
imag
poxviru
infect
hiv
fusion
inhibitor
polypeptid
bind
hydrophob
fusion
region
viral
prevent
undergo
conform
chang
requir
fusion
cell
membran
label
version
peptid
might
therefor
effect
tracer
identifi
site
hiv
replic
nonnucleosid
inhibitor
hiv
revers
transcriptas
rt
interfer
directli
activ
bind
loci
activ
site
number
compound
licens
treatment
hiv
infect
sluiscrem
tachedjian
equival
hiv
rt
encod
human
genom
radiolabel
deriv
drug
might
prove
use
target
site
hiv
replic
potenti
proteas
inhibitor
effect
antivir
drug
first
proven
treatment
hiv
infect
number
differ
compound
approv
clinic
use
recent
licens
darunavir
strong
bind
affin
hiv
proteas
k
suggest
would
make
effect
probe
lefebvr
schiffer
assess
whether
drug
antibodi
promis
imag
probe
necessari
label
one
isotop
list
tabl
attempt
imag
infect
anim
pet
spect
instead
preliminari
evalu
perform
use
cor
hlabel
compound
often
synthes
pharmacokinet
studi
therefor
avail
type
research
three
type
experi
perform
first
vitro
assay
label
drug
ad
liquid
medium
number
flask
well
virusinfect
uninfect
cell
variou
time
point
supernat
remov
cell
rins
harvest
scintil
count
perform
amount
radioact
retain
infect
uninfect
cell
compar
accumul
significantli
larger
quantiti
radiolabel
drug
virusinfect
uninfect
cell
indic
may
also
preferenti
retain
site
infect
vivo
addit
studi
would
includ
test
specif
bind
ad
larg
excess
unlabel
drug
determin
k
label
drug
concentr
bind
site
b
max
kinet
bind
competit
studi
unlabel
analogu
cheng
prusoff
deblasi
et
al
jeffri
et
al
investig
could
move
forward
ex
vivo
experi
virusinfect
uninfect
anim
kill
variou
time
point
necropsi
perform
relev
organ
exampl
lung
influenza
brain
enceph
collect
frozen
thin
section
cut
place
onto
microscop
slide
immers
solut
label
cor
hlabel
drug
rins
remov
unbound
tracer
place
film
phosphor
imag
plate
autoradiographi
saito
et
al
frey
albin
cagnin
et
al
patel
gibson
stumpf
suffici
exposur
time
elaps
film
examin
determin
radiolabel
drug
preferenti
retain
site
viral
infect
check
specif
variou
amount
unlabel
cold
drug
ad
solut
label
compound
determin
compet
bind
site
infect
reduc
detect
signal
addit
thin
section
would
use
immunohistolog
studi
confirm
presenc
virusinfect
cell
time
ex
vivo
studi
perform
investig
carri
vivo
experi
cor
hlabel
drug
administ
infect
uninfect
anim
prefer
small
rodent
appropri
delay
anim
kill
organ
interest
remov
sampl
collect
determin
viral
titer
plaqu
titrat
probe
concentr
scintil
count
autoradiographi
section
prepar
immunohistolog
studi
site
maximum
viral
replic
also
show
highest
level
radioact
much
lower
signal
detect
uninfect
tissu
would
suggest
drug
potenti
virusspecif
probe
ex
vivo
studi
specif
bind
evalu
administ
variou
amount
unlabel
drug
along
label
probe
see
competit
take
place
initi
test
cor
hlabel
drug
confirm
potenti
imag
probe
next
step
work
radiochemist
determin
necessari
precursor
method
synthesi
spect
pet
tracer
synthesi
carri
evalu
new
radiolabel
probe
includ
vitro
andor
ex
vivo
studi
ensur
retain
biolog
activ
time
imag
specialist
consult
design
initi
studi
appropri
anim
model
viral
infect
addit
offer
second
applic
certain
licens
antivir
directli
target
viral
replic
radionuclid
imag
may
also
provid
use
compound
activ
vitro
anim
model
variou
reason
move
forward
licensur
case
deoxyglucos
fail
trial
cancer
drug
wide
use
tracer
pet
imag
might
includ
candid
antivir
nephroor
hepatotox
therapeut
dose
rather
discard
drug
research
consid
evalu
use
virusspecif
imag
probe
